SLC5A2 and hydrops fetalis: In patients with STEMI and an increased risk of HF, treatment with Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors did not show to have a statistically significant impact on the composite outcome of cardiovascular death and first hospitalization for HF compared to the placebo (17, 18).